References
- Lear W, Dahlke E, Murray CA. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg 2007; 11:19–30.
- De-Domingo B, Gonzalez F, Lorenzo P. Gorlin syndrome (nevoid basal cell carcinoma syndrome). Arch Soc Esp Oftalmol 2008; 83:321–324.
- Kelly SC, Ermolovich T, Purcell SM. Nonsyndromic segmental multiple infundibulocystic basal cell carcinomas in an adolescent female. Dermatol Surg 2006; 32:1202–1208.
- Happle R. Nonsyndromic type of hereditary multiple basal cell carcinoma. Am J Med Genet 2000; 95:161–163.
- Sapijaszko MJA. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Ther Lett 2005; 10(6):2–5.
- Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2007; 245:1217–1220.
- Moehrle M, Breuninger H, Schippert W, Häfner HM. Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study [letter]. Dermatol Surg 2010; 36:428–430.
- Carneiro RC, de Macedo EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular basal cell carcinoma. Ophthalmol Plast Reconstr Surg 2010; 26:100–102.
- Ross AH, Kennedy CT, Collins C, Harrad RA. The use of imiquimod in the treatment of periocular tumours. Orbit 2010; 29:83–87.